AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline.
AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands to Germany’s Cheplapharm Arzneimittel in a deal worth up to $309 mil
AstraZeneca is selling off European commercial rights to its high blood pressure drug Atacand to German biotech Cheplapharm, securing $200 million for “company’s new wave of medicines”.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.